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Abstract
This article overviews the basic terms and methodology ap-
proaches in economic analysis in medicine: cost-benefit anal-
ysis, cost-effectiveness analysis, cost-utility analysis and cost-
minimisation analysis. Particular emphasis is put on nuclear
medicine economic evaluation, e.g. FDG - PET studies, sesta-
mibi breast cancer imaging and radioiodine therapy of hyper-
thyroidism.
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Introduction
Health care reforms introduced in most Central and Eastern
European countries after 1989 caused the need to improve eco-
nomic evaluation on every management level of medical deci-
sion-making and medical technology decision-making. The tran-
sition from a state-financed health care system to a semi-market
system forced the implementation of economic evaluation of
medical technology. Medical technology is interpreted here as
drug dispensing, usage of medical equipment, choosing surgery
methods or any other medical intervention, etc. For example
— on the American market, every Health Maintenance Organisa-
tion has a separate team devoted to the economic evaluation of
medical technology, particularly with new technologies. This re-
view presents the basic methods of economic analysis in medi-
cine, with particular emphasis on nuclear medicine applications.
Forms of evaluation
The aim of health economics is to identify the interventions
that produce the best health output with the available resources.
Economic evaluation analysis compares at least two alternative
interventions or activities with regard to costs and consequences.
There are five commonly used forms of economic evaluation
of medical procedures:
— cost-benefit analysis (CBA);
— cost-effectiveness analysis (CEA);
— cost-utility analysis (CUA);
— cost-minimisation analysis (CMA);
— decision analysis (DA).
Cost-benefit analysis
Cost-benefit analysis (CBA) evaluates benefits of health care,
comparing competing alternatives of medical procedures in mon-
etary terms. It is most commonly applied when the benefits of
competing investments are quite different. To express benefits
like saving life or relief of pain in monetary terms in this mode of
analysis is a very complicated problem. Also the market price is
not always equal to that which we are able or willing to pay in
a particular situation (the so-called consumer surplus — for ex-
ample we are willing to pay more for water when we are thirsty).
If medical intervention prolongs the life of the patient, the ben-
efits of health care are valued in monetary terms, using the hu-
man capital approach. By the human capital approach we derive
a valuation for the extended lifetime by the assumption that the
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wages paid to individuals represent a value of the extra life. The
usefulness of this approach is, however, limited, because how
are we to value the health improvements for retired or unemployed
people?
Using the willingness-to-pay analysis, there are two main ways
of estimating benefits from the programme:
— revealed preference — this is the maximum which individu
als would hypothetically pay; most often revealed preference
concerns health risks e.g. for automobile safety belts or re-
ducing indor radon exposure [1];
— expressed preference — this is how much the individual is
able to pay for health state improvement e.g. for hypertension
treatment [2].
Cost-benefit analysis is conducted either by interviews (face
to face or by telephone call) or mail questionnaires used to deter-
mine the willingness to pay. Sometimes it is argued that these
questions are often difficult and ethically hardly acceptable.
Medical applications of cost-benefit analysis are rather in ex-
perimental stage and are not so widely applied, as remaining four
other modes of economic analysis.
Cost-effectiveness analysis
Cost-effectiveness analysis (CEA) is the most suitable tech-
nique when the benefits of competing interventions can be ex-
pressed in the same natural units. Sometimes instead of the final
outcome we use an intermediate marker to measure a benefit.
For example,  if two diagnostic strategies are being compared,
the “cases detected” parameter might be chosen.
Using this kind of technique for analysis, we are looking for an
answer to the question “what is the most efficient way of spending a
given budget?” So in other words what is the cheapest way of pro-
ducing effectiveness units. The results are expressed as cost-effec-
tiveness rate, which show  costs achieved by the effectiveness unit;
CER = costs/health effects (e.g. years of life
gained)
The denominator of a cost/effectiveness ratio is reserved for
the improvement in health associated with an intervention. The
numerator captures changes in resources used associated with
an alternative intervention, expressed in monetary units.
The incremental cost-effectiveness ratio (ICER) is one of the
most general ways to compare a newly emerging strategy with an
existing one. This ratio compares the difference in costs between
the two strategies, divided by the difference in their effectiveness [3].
The main categories of resources used that should be includ-
ed are: the costs of health services, the costs of patient time ex-
pended for the intervention, costs associated with care-giving and
other costs associated with the illness (e.g. child care or travel
expenses) [4]. In spite of the widespread application of cost-ef-
fectiveness analysis in practical use in health care, in fact there is
still a lack of well-defined standards. These disparities can be
traced to a misunderstanding between decision-makers. This fact
was the main motivation for the Panel on Cost-Effectiveness in
Health and Medicine in order to develop the consensus-based
recommendations guiding the conduct of a CEA to improve the
comparability and quality of studies. The Panel’s recommenda-
tions define a reference case, a standard set of methods to serve
as a point of comparison across studies [5, 6].
CEA is important from many different aspects. These include
the following:
— helping nuclear medicine physicians to understand how a given
medical procedure fits into the overall management of a patient;
— providing objective data that justify the role of a particular study;
— allowing the physicians to understand how effectively/poorly
the test can perform, e.g., how low the sensitivity can get, and
yet still be cost-effective;
— allowing the obtaining of answers to “what if” questions, e.g.,
how expensive can a newly emerging technology be, if it should
remain cost-effective in a given set of applications?
— helping nuclear medicine physicians to understand what por-
tion of the receiver-operator  characteristic curve we should
operate to be most cost-effective;
— allowing nuclear medicine physicians to present objective evi-
dence to hospitals, insurance companies and regulatory agen-
cies, leading to a more rapid acceptance and reimbursement
for newly emerging technologies [3].
The application of cost-effectiveness analysis generally focus-
es on the quantity parameters of patient outcome (e.g. number of
pain-free days, number of lives saved or number of metastases
detected, etc.).
Cost-utility analysis
With reference to quantity analysis in CEA, quality analysis
has been created in a form of cost-utility analysis (CUA).
Cost-utility analysis compares results of medical interventions
mentioned in utility units. Usually it expresses the number of addi-
tional years of life produced by medical intervention, with special
regard to the quality of these years. The most commonly used
measure in cost-utility analysis is Quality Adjusted Life Years
(QALY) — 1 year of life gained with medical intervention equals 1
of QALY. Two years of life in a healthy state judged to be halfway
between full health and death would be equivalent to one year in
full health [2]. In general, health state is scaled from
0 (dead) to 1 (optimal health). It is not easy to measure the value
of a healthy state and there are different methods used for this
purpose: standard gamble, time trade off or Visual Analogue Scale,
where the respondent is asked directly. Indirect methods for esti-
mation of health state rely on health classification systems such
as Quality of Well-Being Scale, Health Utilities Index or Euro-Qol.
Cost-minimisation analysis
If the health effects of two alternative interventions are known
to be equal, and only the costs need to be analysed we use cost-
-minimisation analysis (CMA). This least costly alternative is the
most efficient, for example goitre resection or radioiodine therapy
for hyperthyroidism [7–9].
Decision analysis
This is applied when only the health effects of medical inter-
vention are important. Alternative intervention has the some cost,
or costs are not important in a particular decision situation.
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Table 1. Main differences between the modes of economic analysis
Costs Benefits When most
measured measured appropriately used
CBA All relevant costs Benefits valued in To compare alternatives
associated with monetary terms that produce quite
the intervention different benefits
CEA All relevant costs Benefits expressed To compare alternatives
associated with by some common where the outcomes
the intervention measure of effect can be expressed in
a common natural unit
CUA All relevant costs Benefits expressed To compare alternatives
associated with by changes in with quite different
the intervention patient utility. benefits but relies on the
measurement of QALYs
Normally a composite
of the extension of life
weighted by an index
of utility or quality
(QALY)
CMA All relevant costs Benefits assumed to When two alternatives
associated with be identical have the same outcome
the intervention
DA No Benefits measured When only the results
in units comparing of the intervention are
different types of important
medical intervention
The main differences between the modes of economic analy-
sis in medicine are presented in the Table 1.
Important problems in economic analysis
in medicine
The choice of the object of the study
A full economic evaluation should compare at least two alter-
native interventions. Each of them should be real and well-
-defined. The aim of such a study should be well defined, as well
as the patient group on which the study is conducted. Each study
should consider both costs and outcomes.
The perspective of the analysis
It is very important to state the perspective from which the
study will be valued. The strategy most economic from the per-
spective of a hospital may not be the best suited to the health
care system as a whole [1]. Studies based on different perspec-
tives are not comparable and can lead to misunderstandings.
Because health care provides benefits to society as a whole it is
the perspective of society that should be represented in any evalu-
ation. The societal perspective is the most pragmatic choice be-
cause it represents the public interests rather than those of any
particular group.
Modelling
To conduct an economic analysis we often use data provided
by randomised controlled trials or observational studies. Unfortu-
nately clinical studies do not always include economic data or do
not follow up patients for long enough after intervention. We can
complete such insufficient data by modelling.
Modelling techniques enable the extension of evaluation to
beyond what has been observed. They can be used to extrapo-
late the clinical outcomes (like survival) beyond a point observed
in a trial — for example the progression of disease in patients with
asymptomatic AIDS or to transform final outcomes from interme-
diate measures — for example, survival and coronary heart dis-
ease events from cholesterol concentrations [2].
Modelling is often used in pharmacoeconomy, where health
benefits are likely to occur in the future and there is no prospec-
tive date yet.
Time preference and discounting
In many medical interventions benefits and costs may occur
in the future. For example, heart surgery may provide benefits for
patients in the future, but also may create additional future costs,
such as consultations of specialists and additional pharmacother-
apy. Costs and benefits that occur in the future should be reduced
(discounted) to their present value because of “time preference”.
This means that we would rather have something now than in the
future, because the present time has more value for us. The recom-
mended discounted rate varies between 3 and 6% [1].
Uncertainty
Uncertainty often exists around an economic evaluation. There
are three types of uncertainty: uncertainty related to observed data
inputs, uncertainty in relation to modelling  and uncertainty in rela-
tion to analytical methods.
Choice of the proper economic analysis mode
The choice of the proper economic analysis mode depends
on the kind of question which we want to be answered. If we want
to know if the benefits are greater than the costs, then CBA should
be used. If we have an established goal and a budget for this
goal, we are looking for a form of evaluation which will give us an
answer as to which medical intervention will give us maximum
returns within a given budget. Cost-effectiveness analysis or cost-
utility analysis are most suited in this case. If the outcomes of two
or more alternative methods are equal, we use the cost-minimisa-
tion analysis.
Examples of the results of economic evalua-
tion in nuclear medicine
As nuclear medicine physicians, we are often not informed
how the result of particular imaging modality fully affects a partic-
ular patient’s entire medical/surgical management. This is per-
haps best exemplified by oncology management, which is com-
plex and with rapidly changing management options [3]. We would
like to present below some examples of utilising economical ana-
lysis in nuclear medicine.
FDG-PET
In patients with non-small cell lung cancer (NSCLC), FDP-PET
is considered superior to CT in detection of hilar and mediastinal
lymph node metastases [10–13]. Gambhir et al. [14] used deci-
sion tree analysis to assess the cost-effectiveness of a PET-based
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strategy for the staging of NSCLC. Their first decision tree was
constructed conservatively, requiring mediastinoscopy and biop-
sy to confirm pathological CT or PET results, so that no patient
with a surgically curable disease would miss the opportunity of
receiving surgery. By avoidance of unnecessary surgery the CT
and PET strategy showed a saving of $1154 per patient without
a loss of life expectancy as compared with the alternative strategy
of CT alone. A less conservative decision tree, in which only pa-
tients with non-concordant imaging results had the biopsy, was
also analysed in this study. Then CT and PET strategy showed
savings of $2267 per patient but missed 1.7% of the potentially
curable patients. A possible loss of QALYs in this algorithm was
not analysed in this study.
In patients with radiographically indeterminate solitary pulmo-
nary nodules, PET is useful for determining the probability of can-
cer. Although the specificity of PET seemed to be lower than its
sensitivity, better specificity of PET over CT leads to its greater
potential utility in avoiding unnecessary surgery in patients with
benign solitary pulmonary nodules [15].
Although PET was more expensive than CT, the additional cost
of PET would be minuscule compared with the cost savings
achieved through the avoidance of unnecessary thoracotomy. If
there were only a 1 in 20 chance that a patient with a negative PET
study would have a malignant solitary pulmonary nodule, most
clinicians would opt for watchful waiting rather than proceeding
immediately with an unnecessary diagnostic thoracotomy.
Both indications for FDG-PET (NSCLC and solitary pulmonary
nodules) were met with acceptance by the Health Care Financing
Administration in the United States [16, 17].
Sestamibi breast cancer imaging
The decision tree analysis by Hillner [18] compared sestamibi
breast imaging, stereotaxic core biopsy and surgical biopsy as
breast evaluation strategies for hypothetical cohorts with non-pal-
pable breast lesions. Since sestamibi imaging was the lower-cost
strategy, the incremental cost-effectiveness of core biopsy was
estimated at $18,000 for each early invasive and in situ detected
cancer. The sestamibi strategy delayed diagnosis for 6 months in
2.5 out of 100 invasive cancers. The consequences of a 6-month
delay in diagnosis for patient survival through an increased risk of
micrometastatic disease are unknown. The clinically relevant cost-
effectiveness ratio therefore remained unclear. A contrary conclu-
sion from the decision tree analysis might be drawn: the incre-
mental cost of $18,000 for the additional early diagnosis of can-
cer might be acceptable in comparison with the costs of annual
mammographic screening of $10,000–$190,000 per QALY.
The assumption of 90% sensitivity of sestamibi breast imaging
for invasive cancer and in situ cancer seems however too optimis-
tic, judging by the average findings presented in the other clinical
data. Thus, the use of sestamibi breast imaging as an alternative to
biopsy is only applicable in a selected patient population [1].
Radiodine treatment of Graves’ disease
Another interesting example of cost-effectiveness analysis
concerns radioiodine or antithyroid drugs as first-line therapy of
hyperthyroidism due to Graves’ disease [19]. As first-line therapy
of hyperthyroidism caused by Graves’ disease, antithyroid drugs
are preferred in Europe, whilst radioiodine therapy is preferred in
the USA. Radioiodine therapy has been considered to be more
economic in Germany, since the new recommendations by the
Federal German Radiation Protection Committee (SSK) for pa-
tient discharge guidelines. This analysis took into account the long-
term relapse rate of conservative or radioiodine therapy, costs
and sensitivity of diagnostic tests, drops in productivity and a dis-
count factor. Costing models included the costs of follow-up care
over 30 years. The costs of the hospitalisation for radioiodine ther-
apy were calculated for 300 patients, discharged with 250 MBq
I-131 residual activity. Antithyroid drugs were considered cost-ef-
fective when they achieved a relapse rate of 50% or less, a cut in
the number of tests needed and reduced working hours. Failure
to meet any one of these conditions made primary radioiodine
therapy more cost-effective in 1593 of 1944 calculated costing
models. Repeated conservative therapies will increase clearly the
overall costs. The conclusion is that radioiodine is a cost-effec-
tive, first-line therapy in patients with a special risk of relapse after
primary conservative therapy.
Summary
Decision-making in medical financing of technologies requires
the best information and medical expertise based on credible eval-
uation. In the near future, especially in larger hospitals, hospital
information systems will track patients through every aspect of
their medical care [3]. It should be a standard that every decision
about financing a new or old medical technology will be made
after the conducting of economic analysis, based on evidence
and not on opinions or persuasions.
The idea of evidence-based health care is becoming more
and more popular in the world. It is obvious we have to conduct
an economic analysis to provide more benefits for patients and
society in a modern health care system. But it is also very impor-
tant that as physicians we must accept that some applications of
our imaging studies are not cost-effective and should not be uti-
lised purely for economic gains.
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